2 unchanged sentences
Our common stock is traded on The Nasdaq Global Select Market under the symbol DOCU.
−Removed: DocuSign, Inc.| 2022 Form 10-K | 41
Holders of our Common Stock
11 unchanged sentences
Data for the S&P 500 Index and the S&P 500 Information Technology Index assume reinvestment of dividends.
+Added: DocuSign, Inc.| 2023 Form 10-K | 39
The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our common stock.
Recent Sales of Unregistered Equity Securities
−Removed: DocuSign, Inc.| 2022 Form 10-K | 42
Use of Proceeds
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
+Added: In March 2022, our board of directors authorized and approved a stock repurchase program of up to $200.0 million of our outstanding common stock.
+Added: Repurchases of our common stock may be effected from time to time, either on the open market, in block trades, in privately negotiated transactions, and through other transactions in accordance with applicable securities laws.
+Added: The program does not obligate us to repurchase any specific number of shares and may be discontinued at any time.
+Added: The program has no expiration date and will continue until otherwise suspended, terminated, or modified at any time for any reason by our board of directors.
+Added: No repurchases occurred under the program during the three months ended January 31, 2023.
+Added: As of January 31, 2023, the approximate dollar value of shares that may yet be purchased under the stock repurchase program was $137.0 million.
+Added: See Note 11 of this Annual Report on Form 10-K for additional information related to stock repurchases.
+Added: DocuSign, Inc.| 2023 Form 10-K | 40
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.